Kathrin Hedegger1, Franziska Stumpf1, Helmut Blum2, Alexander Graf2, Roland Michael Schmid3, Marina Lesina3, Hana Algül3, Marlon Roberto Schneider1, Maik Dahlhoff4. 1. Institute of Molecular Animal Breeding and Biotechnology, Gene Center of the LMU Munich, Feodor-Lynen-Str. 25, 81377, Munich, Germany. 2. Laboratory for Functional Genome Analysis (LAFUGA), Gene Center of the LMU Munich, Munich, Germany. 3. Second Department of Internal Medicine, Klinikum Rechts Der Isar, Technical University of Munich, Munich, Germany. 4. Institute of Molecular Animal Breeding and Biotechnology, Gene Center of the LMU Munich, Feodor-Lynen-Str. 25, 81377, Munich, Germany. dahlhoff@lmb.uni-muenchen.de.
Abstract
BACKGROUND: The EGFR ligand betacellulin (BTC) has been previously shown to protect mice against experimentally induced acute pancreatitis (AP). BTC binds both autonomous ERBB receptors EGFR and ERBB4. In this study, we evaluated the mechanism underlying the protection from AP-associated inflammation in detail. METHODS: AP was induced with cerulein or L-arginine and investigated in a pancreas-specific ERBB4 knockout and in an EGFR knockdown mouse model (EgfrWa5/+). Pancreatitis was evaluated by scoring inflammation, necrosis, and edema, while microarrays were performed to analyze alterations in the transcriptome between mice with AP and animals which were protected against AP. The intracellular domain (ICD) of ERBB4 was analyzed in different cell compartments. RESULTS: While the pancreas of BTC transgenic mice in the background of EgfrWa5/+ is still protected against AP, the BTC-mediated protection is no longer present in the absence of ERBB4. We further demonstrate that BTC activates the ICD of ERBB4, and increases the expression of the extracellular matrix (ECM) proteins periostin and matrix gla protein as well as the ECM modulators matrix metalloproteinases 2 and 3, but only in the presence of ERBB4. Notably, the increased expression of these proteins is not accompanied by an increased ECM amount. CONCLUSIONS: These findings suggest that BTC derivates, as a drug, or the ERBB4 receptor, as a druggable target protein, could play an important role in modulating the course of AP and even prevent AP in humans.
BACKGROUND: The EGFR ligand betacellulin (BTC) has been previously shown to protect mice against experimentally induced acute pancreatitis (AP). BTC binds both autonomous ERBB receptors EGFR and ERBB4. In this study, we evaluated the mechanism underlying the protection from AP-associated inflammation in detail. METHODS: AP was induced with cerulein or L-arginine and investigated in a pancreas-specific ERBB4 knockout and in an EGFR knockdown mouse model (EgfrWa5/+). Pancreatitis was evaluated by scoring inflammation, necrosis, and edema, while microarrays were performed to analyze alterations in the transcriptome between mice with AP and animals which were protected against AP. The intracellular domain (ICD) of ERBB4 was analyzed in different cell compartments. RESULTS: While the pancreas of BTCtransgenic mice in the background of EgfrWa5/+ is still protected against AP, the BTC-mediated protection is no longer present in the absence of ERBB4. We further demonstrate that BTC activates the ICD of ERBB4, and increases the expression of the extracellular matrix (ECM) proteins periostin and matrix gla protein as well as the ECM modulators matrix metalloproteinases 2 and 3, but only in the presence of ERBB4. Notably, the increased expression of these proteins is not accompanied by an increased ECM amount. CONCLUSIONS: These findings suggest that BTC derivates, as a drug, or the ERBB4 receptor, as a druggable target protein, could play an important role in modulating the course of AP and even prevent AP in humans.
Authors: Hahn-Jun Lee; Kwang-Mook Jung; Yang Z Huang; Lori B Bennett; Joanne S Lee; Lin Mei; Tae-Wan Kim Journal: J Biol Chem Date: 2001-12-10 Impact factor: 5.157
Authors: Christine M Ardito; Barbara M Grüner; Kenneth K Takeuchi; Clara Lubeseder-Martellato; Nicole Teichmann; Pawel K Mazur; Kathleen E Delgiorno; Eileen S Carpenter; Christopher J Halbrook; Jason C Hall; Debjani Pal; Thomas Briel; Alexander Herner; Marija Trajkovic-Arsic; Bence Sipos; Geou-Yarh Liou; Peter Storz; Nicole R Murray; David W Threadgill; Maria Sibilia; M Kay Washington; Carole L Wilson; Roland M Schmid; Elaine W Raines; Howard C Crawford; Jens T Siveke Journal: Cancer Cell Date: 2012-09-11 Impact factor: 31.743
Authors: Weiwen Long; Kay-Uwe Wagner; K C Kent Lloyd; Nadine Binart; Jonathan M Shillingford; Lothar Hennighausen; Frank E Jones Journal: Development Date: 2003-09-03 Impact factor: 6.868
Authors: Kathrin Hedegger; Hana Algül; Marina Lesina; Andreas Blutke; Roland M Schmid; Marlon R Schneider; Maik Dahlhoff Journal: Mol Oncol Date: 2020-05-18 Impact factor: 6.603